Cargando…
Treatment and relapse of interstitial lung disease in nivolumab‐treated patients with non–small cell lung cancer
Nivolumab, a human monoclonal antibody against programmed death‐1, is approved for the treatment of non–small cell lung cancer (NSCLC). Although nivolumab is generally well tolerated, it can cause interstitial lung disease (ILD), a rare but potentially fatal immune‐related adverse event. Currently,...
Autores principales: | Sata, Masafumi, Sasaki, Shinichi, Oikado, Katsunori, Saito, Yoshinobu, Tominaga, Junya, Sakai, Fumikazu, Kato, Terufumi, Iwasawa, Tae, Kenmotsu, Hirotsugu, Kusumoto, Masahiko, Baba, Tomohisa, Endo, Masahiro, Fujiwara, Yutaka, Sugiura, Hiroaki, Yanagawa, Noriyo, Ito, Yoshihiko, Sakamoto, Takahiko, Ohe, Yuichiro, Kuwano, Kazuyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019226/ https://www.ncbi.nlm.nih.gov/pubmed/33125784 http://dx.doi.org/10.1111/cas.14715 |
Ejemplares similares
-
Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non–small cell lung cancer
por: Saito, Yoshinobu, et al.
Publicado: (2021) -
Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
por: Baba, Tomohisa, et al.
Publicado: (2023) -
Nivolumab‐induced radiation recall pneumonitis in non‐small‐cell lung cancer patients with thoracic radiation therapy
por: Noda‐Narita, Shoko, et al.
Publicado: (2022) -
Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan
por: Ohe, Yuichiro, et al.
Publicado: (2020) -
Prognostic Factors in Interstitial Lung Disease Associated with Primary Sjögren’s Syndrome: A Retrospective Analysis of 33 Pathologically–Proven Cases
por: Enomoto, Yasunori, et al.
Publicado: (2013)